XOMA Corporation (NASDAQ:XOMA) most recently reported quarterly actual earnings per share of $-0.13 for the period ending on 2016-06-30. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $-0.12. The difference between the estimate and the actual EPS was $-0.01 creating a surprise factor of -8.33%. Currently, the company has an impact score of 77. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0.466. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.
In taking a look at where the stock might be headed, analysts have a consensus price target of $1.09 on the shares. The most bullish brokerage firm has a $1.42 target, while the most bearish sees the stock headed towards $0.85. This is according to the 3 estimates taken into consideration by Zacks Research.
In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.6. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 3 recommendations taking into account in order to arrive at this number. Of the 3, 1 have a Strong Buy rating and 0 are rating it a Buy.
XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company’s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet, and represent potential new therapeutic approaches to the treatment of diabetes and several diseases that have insulin involvement. On January 17, 2012, it announced that it had acquired certain the United States rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON (perindopril erbumine), a marketed angiotensin converting enzyme (ACE) inhibitor, and three fixed-dose combination (FDC) product candidates where a form of perindopril (perindopril arginine) is combined with another active ingredient.
XOMA Corporation - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.